Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s closing ...
Johnson & Johnson just announced a major acquisition to boost its position in the biopharmaceutical market. The company today said it's buying Intra-Cellular Therapies, a company developing medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback